

## Monthly Fact Sheet

### 31 January 2021

<b>Launch Date</b>	20 October 2014
<b>Fund Size</b>	£1049m
<b>Historic Yield*</b>	0.08%

#### Share Price (as at 31.01.21)

Shares	Income	Accumulation
B Shares	301.94p	319.24p

### Investment Objective and Policy

The objective of the Fund is to achieve long-term capital growth by investing primarily in a portfolio of fully listed and AIM traded UK equities.

### Fund Managers



#### James Baker

a history graduate from Cambridge University, has over 30 years of equity market experience on both buy and sell sides, specialising for all of his career in UK Small and Mid caps stock selection. He has

worked for several organisations over the years, but most notably spent 11 years from 1999 to 2011 as part of the ABN Amro, Small Mid cap sales team, which was consistently top ranked by Extel. Prior to joining Chelverton he worked as the Assistant fund manager on the Rathbone UK Recovery Fund.



#### Edward Booth

graduated from the London School of Economics with a degree in Economics with Economic History, and qualified as a Chartered Accountant at Deloitte, where he focused on the

Insurance sector. Prior to joining Chelverton, he worked as a Business Analyst for Barclays, focusing on a number of areas including Investment Bank Revenue and Group Capital performance.

\*The historic yield reflects distributions over the past 12 months as a percentage of the bid price of the B share class as at the date shown. It does not include any initial charge and investors may be subject to tax on their distributions.

# MI Chelverton UK Equity Growth Fund

## Monthly Manager Commentary

UK equities started the year strongly as investors celebrated the December BREXIT trade deal with the UK market, which had lagged the major overseas markets for most of 2020, being seen as investable again. This strong performance was concentrated on large and mid-caps, with a bias towards cyclicals, and as such it left the Growth Fund trailing in its wake. However, as January progressed, confidence was eroded by the resurgence of the COVID-19 pandemic, with the resultant lockdowns undermining investors' expectations, enabling the Fund's performance to catch-up, to the extent that it was comfortably ahead of its IA UK All Companies benchmark by the end of the month.


Healthcare stocks, as was the case through much of 2020, continued to generate strong returns with Renalytix (kidney diagnostics) and Angle (cancer diagnostics) being the Fund's top contributors. Two of the Fund's larger stocks, namely Brooks MacDonald and Clinigen, which had both been in the doldrums for some time, also contributed strongly as they started to be re-rated. Finally, AFH Financial rose on the back of an agreed take-over approach.

On the trading front, we continued to add to the Fund's UK infrastructure exposed stocks in the construction sector, namely Balfour Beatty and Breedon. We started a new holding in GlobalData, one of our long-term favourites in the media sector, and topped up several holdings on share price weakness, including Ultra Electronics, Liontrust Asset Management, IG Design, Essentra and RWS Holdings. Conversely, we took some profits across a number of the Fund's strongest performers on valuation grounds, trimming several healthcare holdings, namely Maxcyte, Renalytix, Angle and EKF Diagnostics, as well as top-slicing Gamesys, Inspec, dotDigital and Ideagen.

At the time of writing, we are seeing a wave of IPO activity particularly in the Technology sector, with business owners able to enjoy the high valuations available after the sector's strong performance in 2020, as it proved its resilient through the pandemic. To date, such fund raisings have been snatched up, notwithstanding their stretching valuations, and we have not participated in any of the technology IPOs. Furthermore, given the high ratings, we have continued to whittle down some of the Fund's existing Technology holdings.

At the other end of the spectrum, we are seeing a pick-up in takeover activity, largely focused on the value end of the market, with approaches for the likes of Scapa, Signature Aviation, Marston's, Aggreko and McCarthy and Stone, as Private Equity in particular look to acquire undervalued UK listed assets now the BREXIT deal is out of the way. We continue to gently build up exposure to some of our preferred cyclical names, which we hope will rebound strongly as and when lockdown restrictions are eased.

### Performance Since Launch (%)



Source: Morningstar, NAV to NAV, B Shares Acc, Total Return to 31.01.2021

### Cumulative Performance

	1 m	3 m	1 yr	3 yrs	5 yrs	Since Launch
Fund (%)	2.27	22.29	17.94	47.09	150.83	219.57
Rank in sector	5/239	47/239	1/238	1/228	1/215	1/208
Quartile	1st	1st	1st	1st	1st	1st
IA UK All Companies (%)	-0.90	17.98	-4.76	1.94	34.90	44.42

Source: Morningstar, NAV to NAV, B Shares Acc, Total Return to 31.01.2021

### Calendar Year Performance (%)

	YTD	2020	2019	2018	2017	2016
Fund	2.27	15.93	40.58	-8.91	33.35	19.26
IA Sector (%)	-0.90	-6.17	22.37	-11.15	14.05	11.04

Source: Morningstar, NAV to NAV, B Shares Acc, Total Return to 31.01.2021



© Morningstar 2021. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied, adapted or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information, except where such damages or losses cannot be limited or excluded by law in your jurisdiction. Past financial performance is no guarantee of future results.

## Monthly Fact Sheet

**31 January 2021**

**ACD**  
Maitland Institutional Services Limited

**Investment Advisor**  
Chelverton Asset Management Limited

**Administrator**  
Maitland Institutional Services Limited

**Income Paid** Annually

**XD Dates** 31 December

**Valuation** 12 Noon

### Codes (B Shares)

	Income	Accumulation
Sedol	BP85595	BP855B7
ISIN	GB00BP855954	GB00BP855B75

### Annual Management Fee (%)

B Shares 0.75

### Minimum Investment

B Shares £1,000

### Ongoing Charge (%)

B Shares 0.87

**Dealing Line** 0345 305 4217

**Dealing Fax** 0845 280 0188

### FURTHER INFORMATION

Please contact Spring Capital Partners, in the first instance.

**Tel** +44 (0)20 3195 0076

**Email** chelverton@springcapitalpartners.com

**Visit** springcapitalpartners.com



# MI Chelverton UK Equity Growth Fund

## Top 20 Holdings

Holding	Sector	% of Portfolio
1. Brooks MacDonald	Financials	1.8
2. RWS Holdings	Support Services	1.7
3. Future	Media	1.7
4. Volution Group	Construction	1.6
5. Clinigen	Healthcare	1.6
6. Premier Foods	Consumer	1.5
7. Inspec Group	Consumer	1.4
8. IMImobile	Technology	1.3
9. Tyman	Construction	1.3
10. CentralNic	Technology	1.3
11. Vitec Group	Media	1.2
12. Augean	Support Services	1.2
13. Incheape	Support Services	1.1
14. IG Design Group	Consumer	1.1
15. Curtis Banks Group	Financials	1.1
16. Sigmaroc	Construction	1.1
17. Renew Holdings	Support Services	1.1
18. Elementis	Industrials	1.1
19. Alliance Pharma	Healthcare	1.0
20. Volex	Industrials	1.0

Source: Chelverton Asset Management Limited

## Sector Breakdown

	% of Portfolio
Technology	16.7
Support Services	12.7
Healthcare	11.6
Financials	10.6
Consumer	9.7
Construction	9.0
Media	8.2
Industrials	7.9
Resources	3.8
Aerospace & Defence	2.6
Telecoms	0.8
Cash	6.4

## Market Cap Breakdown

	% of Portfolio	No. of Stocks
Above £1bn	17.1	20
£500m - £1bn	21.7	24
£250m - £500m	21.9	27
£100m - £250m	24.8	42
Below £100m	8.1	29
Cash and Income	6.4	N/A
<b>Total</b>	<b>100.0</b>	<b>142</b>

Source: Chelverton Asset Management Limited

Disclaimer: This fund invests in smaller companies and carries a higher degree of risk than funds investing in larger companies. The shares of smaller companies may be less liquid and their performance more volatile over shorter time periods. The fund can also invest in smaller companies listed on the Alternative Investment Market (AIM) which also carry the risks described above. This document is provided for information purposes only and should not be interpreted as investment advice. If you have any doubts as to the suitability of an investment, please consult your financial adviser. The information contained in this document has been obtained from sources that Chelverton Asset Management Limited ("CAM") considers to be reliable. However, CAM cannot guarantee the accuracy or completeness of the information provided, and therefore no investment decision should be based solely on this data. Past performance is not a guide to future performance. This document is issued by CAM, authorised and regulated by the Financial Conduct Authority. This document does not represent a recommendation by CAM to purchase shares in this Fund. The contents of this document are intended for Professional Investors and Eligible Counterparties only. We recommend private investors seek the services of a Financial Adviser. Maitland Institutional Services Limited are the Authorised Corporate Director of this fund and prospectuses for the fund are obtainable directly from them. Please email [Chelverton@maitlandgroup.co.uk](mailto:Chelverton@maitlandgroup.co.uk) or call +44 (0)345 305 4217.